Skip to main content

AbCellera Biologics Inc.

corporate_fare Company Profile

AbCellera Biologics Inc.

ABCL·NASDAQ·Life Sciences·CIK 0001703057

AbCellera is a clinical-stage biotechnology company that discovers and develops antibody medicines for medical needs. The company has developed a platform for advancing antibody drug programs, which it uses to address challenging targets like complex transmembrane proteins and novel modalities such as multispecifics and antibody-drug conjugates. While AbCellera previously used its platform for partner programs, it now focuses on building its own internal pipeline of drug assets. In 2025, AbCellera initiated clinical trials for its first two internal drug candidates. ABCL635, a potential non-hormonal medicine for moderate-to-severe vasomotor symptoms (VMS), or hot flashes, is in a Phase 2 clinical trial in Canada. ABCL575 is in a Phase 1 clinical trial in Canada as a potential medicine for atopic dermatitis and other inflammation and immunology (I&I) conditions. The company also nominated two additional development candidates, ABCL688 and ABCL386. AbCellera opened its clinical manufacturing facility in 2025, completing an investment in its integrated platform. As of December 31, 2025, AbCellera had approximately $700 million in available liquidity. The company's strategy is to create innovative medicines for patients, without focusing on specific indications.

AbCellera Biologics Inc. (NASDAQ:ABCL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for ABCL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for ABCL spans 8-K, 424B5, 10-Q.

Recent high-impact activity:

  • AbCellera Q3: Loss Narrows to $40.8M, $890M Liquidity After $200M Raise
  • AbCellera Narrows Q3 Loss to $40.8M as ABCL635 Phase 2 Data Drives $200M Raise
  • AbCellera Prices $200M Oversubscribed Offering at $9.75/Share
  • AbCellera Prices Oversubscribed $200M Offering at $9.75, Above Recent Lows
  • AbCellera Launches $200M Stock Offering on Heels of ABCL635 Phase 2 Win

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$75.13M
Net Income
-$146.41M
Diluted EPS
-$0.49
Op. Cash Flow
-$131.29M
Free Cash Flow
-$174.07M
Operating Income
-$217.1M
Cash & Equivalents
$128.51M
Debt / Equity
0.00×
Net Margin
-194.9%
Shares Outstanding
300.6M sh
Source: 10-K · filed 2026-02-24 · accession 0001703057-26-000012

Short Interest & Short Volume

8.49 days to cover

FINRA reported short interest of 29,023,512 shares in ABCL as of the October 30, 2026 settlement, a 6.2% decrease from the prior period — about 8.5 days to cover at its recent average daily volume. On November 19, 2026, 38.5% of ABCL volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)29,023,512 shares as of October 30, 2026
Change vs prior period▼ 6.2%
Days to cover8.49 at avg daily volume of 3,420,126
Daily short volume (FINRA facilities)38.5% of 1,103,534 shares on November 19, 2026
5-day average short volume39.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for ABCL, detected from its recent SEC filings · based on capital-structure filings through 2026-08-11.

1 recent capital raise

$200M Equity Offering Launched · Proceeds to Fund ABCL635 Advancement

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with A →
$10.1 -3.53% today
52-week range · as of 2026-11-09 $2.75 – $15.02
Market cap
$3.31B
Volume
671.1K (0.2× avg)
3-mo avg 3.2M
Live data · 2026-11-20 15:11 UTC · Market open

show_chartPrice Chart

Loading chart...

feed ABCL - Latest Insights

ABCL
Nov 09, 2026, 4:22 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $12.54
Real-time Price: $10.10 info
Change: -$2.44 (-19%) info
Market Cap: $3.309B info
ABCL
Nov 09, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $12.90
Real-time Price: $10.10 info
Change: -$2.80 (-22%) info
Market Cap: $3.309B info
ABCL
Aug 13, 2026, 4:33 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $10.97
Real-time Price: $10.10 info
Change: -$0.870 (-8%) info
Market Cap: $3.309B info
ABCL
Aug 13, 2026, 12:05 AM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $10.32
Real-time Price: $10.10 info
Change: -$0.220 (-2%) info
Market Cap: $3.309B info
ABCL
Aug 11, 2026, 4:59 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $9.32
Real-time Price: $10.10 info
Change: +$0.780 (+8%) info
Market Cap: $3.309B info
ABCL
Aug 11, 2026, 4:01 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $9.76
Real-time Price: $10.10 info
Change: +$0.340 (+3%) info
Market Cap: $3.309B info
ABCL
Aug 10, 2026, 2:12 PM EDT
Source: Benzinga
Importance Score:
9
Price at Filing: $9.37
Real-time Price: $10.10 info
Change: +$0.730 (+8%) info
Market Cap: $3.309B info
ABCL
Aug 10, 2026, 7:49 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $8.86
Real-time Price: $10.10 info
Change: +$1.24 (+14%) info
Market Cap: $3.309B info
ABCL
Aug 10, 2026, 7:15 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $9.43
Real-time Price: $10.10 info
Change: +$0.6672 (+7%) info
Market Cap: $3.309B info
ABCL
Aug 07, 2026, 5:47 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $7.49
Real-time Price: $10.10 info
Change: +$2.61 (+35%) info
Market Cap: $3.309B info
ABCL
Aug 07, 2026, 4:43 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.27
Real-time Price: $10.10 info
Change: +$2.83 (+39%) info
Market Cap: $3.309B info
ABCL
Aug 05, 2026, 4:28 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $5.68
Real-time Price: $10.10 info
Change: +$4.42 (+78%) info
Market Cap: $3.309B info
ABCL
Jul 29, 2026, 11:38 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.33
Real-time Price: $10.10 info
Change: +$4.77 (+89%) info
Market Cap: $3.309B info
ABCL
Jul 06, 2026, 2:53 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.77
Real-time Price: $10.10 info
Change: +$2.34 (+30%) info
Market Cap: $3.309B info
ABCL
Jun 17, 2026, 12:38 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $5.71
Real-time Price: $10.10 info
Change: +$4.40 (+77%) info
Market Cap: $3.309B info
ABCL
Jun 17, 2026, 7:00 AM EDT
Source: PR Newswire
Importance Score:
9
Price at Filing: $5.13
Real-time Price: $10.10 info
Change: +$4.97 (+97%) info
Market Cap: $3.309B info
ABCL
Jun 05, 2026, 12:03 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.80
Real-time Price: $10.10 info
Change: +$4.30 (+74%) info
Market Cap: $3.309B info
ABCL
May 11, 2026, 4:18 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.89
Real-time Price: $10.10 info
Change: +$5.21 (+107%) info
Market Cap: $3.309B info
ABCL
May 11, 2026, 4:14 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $5.58
Real-time Price: $10.10 info
Change: +$4.52 (+81%) info
Market Cap: $3.309B info
ABCL
May 11, 2026, 4:11 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.58
Real-time Price: $10.10 info
Change: +$4.52 (+81%) info
Market Cap: $3.309B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets